Nectar Lifesciences Quarterly Results
Nectar Lifesciences quarterly results. In Mar 2026, Nectar Lifesciences (NECLIFE) reported revenue ₹6 Cr and net profit ₹-68 Cr. Review NECLIFE earnings multiple to evaluate earnings-based valuation against sector peers.
NECLIFE Quarterly Results — Revenue, Profit & EPS Highlights
Nectar Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Nectar Lifesciences marketcap in USD to track the company's total market size over time.
- Revenue of ₹6 Cr in Mar 2026 (+100.0% vs Jun 2026)
- Net Profit of ₹-68 Cr in Mar 2026 (-353.3% vs Jun 2026, +47.7% vs Mar 2025)
- EBITDA of ₹-83 Cr in Mar 2026 (-232.0% vs Jun 2026)
- Earnings Per Share of ₹-3.38 in Mar 2026 (-327.8% vs Jun 2026)
Nectar Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NECLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6 | 3 | 0 | 0 | 6 | 100.0% | - |
| Net Profit (₹ Cr) | -68 | -15 | -176 | -130 | -63 | - | - |
| EBITDA (₹ Cr) | -83 | -25 | -176 | -130 | -63 | - | - |
| EPS (₹) | -3.38 | -0.79 | -7.85 | -5.80 | -2.82 | - | - |
| Operating Margin (%) | 0.0% | -277000.0% | 0.0% | 0.0% | -1212.0% | - | - |
NECLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
Nectar Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Nectar Lifesciences share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NECLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nectar Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1804.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 159.7 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9550.0 | 2,986 | 751 | -5.0% | - | 25.2% | 337.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1159.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 2050.0 | 1,823 | 282 | -10.5% | - | 15.5% | 396.5 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores